Dr. Louis Robert Lambiase, MD

Dr. Lambiase practices at Baptist Medical Center South in Montgomery, Alabama, part of University of Alabama at Birmingham.

Dr. Lambiase's NPI, 1245207513, was assigned on March 4, 2006. Dr. Lambiase graduated from University of Miami, Lm Miller School of Medicine in 1987. Dr. Lambiase holds Alabama license 42770.

Dr. Lambiase's primary practice is Baptist Medical Center South, at 2105 East South Boulevard, Montgomery, AL 36116 in Montgomery County. The practice phone is (334) 288-2100.

Dr. Lambiase's primary practice is Baptist Medical Center South in Montgomery, Alabama, part of University of Alabama at Birmingham. Dr. Lambiase is also affiliated with Prattville Baptist Hospital. The medical group on file is Montgomery Cardiovascular Associates, P.C. Dmand AI also links Dr. Lambiase to 1 more group practice or clinic and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lambiase practices, 4 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Lambiase's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dmand AI has Dr. Lambiase's licenses on file in 2 states: Alabama and Tennessee.

CMS data shows 149 Medicare services from Dr. Lambiase across 8 procedure codes in 2024, for 120 Medicare patients. Medicare paid $11,478 for them.

CMS counts 120 Medicare patients who saw Dr. Lambiase in 2024. The largest group is 65 to 74, with 54 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 21% are also on Medicaid. Their average risk score is 2.10, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lambiase's median patient age at 66, with 59% women.

In 2024, Dr. Lambiase wrote 354 Medicare Part D claims for 140 patients. 60% of them were for generic drugs. CMS names the drug for 230 of them, across 7 drugs with 11 or more claims each, at $212,478 in total drug cost. In 2023, CMS named 170 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Lambiase for performance year 2024, reported as part of a group. Dr. Lambiase accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 34 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Lambiase, more than 57% of the clinicians it reports for that procedure.

Dmand AI links 2 papers to Dr. Lambiase, published from 2013 to 2016. Dr. Lambiase's most frequent co-authors are Venkata Sandeep Akshintala, MD, Tiffany Chua, MD and Gregory A. Cote, MD, MS.

Dmand AI links Dr. Lambiase to 1 clinical trial. Conditions studied include Rectal Diseases and Colorectal Neoplasms.

CMS Open Payments shows 12 general payments to Dr. Lambiase from 6 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 93% of the total. Celgene Corporation paid the most, $85.

Dr. Lambiase graduated from University of Miami, Lm Miller School of Medicine in 1987.